8/16/2010 7:38:46 AM
Xconomy -- MLC Dx, a San Francisco-based maker of molecular diagnostics, has secured $5.9 million in a Series B financing, according to a report in VentureWire. Mohr Davidow Ventures participated in the round, VentureWire said. MLC Dx is led by CEO Thomas Willis, who previously ran another Mohr Davidow portfolio company, ParAllelle Bioscience, before it was sold to Santa Clara, CA-based Affymetrix in 2005.
comments powered by